Shanghai Obio Technology (Group) Corp. Target Price for 2026

Shanghai Obio Techno...

SHSE:688238

HK$ 7,00

HK$0,00 (0,00%)

7,00 HK$

HK$0,00 (0,00%)

End-of-day quote: 04/07/2026

Shanghai Obio Technology (Group) Corp. Stock Value

According to analysts, the current valuation of SHSE:688238 is Buy.

Buy

Shanghai Obio Technology (Group) Corp. Company Info

EPS Growth 5Y

-23,34%

Market Cap

HK$4,41 B

Long-Term Debt

HK$0,13 B

Quarterly earnings

04/21/2026

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2013

Industry

Health Care

Country

China

Website

Shanghai Obio Technology (Group) Corp.

ISIN Number

CNE1000059N9

Website

http://www.obiosh.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$11,61

65.86%

Last Update: 04/07/2026

Analysts: 1

Highest Price Target HK$11,61

Average Price Target HK$11,61

Lowest Price Target HK$11,61

In the last five quarters, Shanghai Obio Technology (Group) Corp.’s Price Target has risen from HK$4,34 to HK$8,20 - a 88,94% increase. One analysts predict that Shanghai Obio Technology (Group) Corp.’s share price will increase in the coming year, reaching HK$11,61. This would represent an increase of 65,86%.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Obio Technology (Group) Corp. do?

Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, focuses on the development of gene therapy vectors. Business Segments The company’s business segments are structured to provide comprehensive technical services across the entire value chain of cell and gene therapy. The company’s main business segments include: Cell and Gene Therapy CRO Services: The company offers a wide range of CRO services tailored to the needs of research institutes, medical institutions, and pharmaceutica...

Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, focuses on the development of gene therapy vectors.

Business Segments

The company’s business segments are structured to provide comprehensive technical services across the entire value chain of cell and gene therapy. The company’s main business segments include:

Cell and Gene Therapy CRO Services: The company offers a wide range of CRO services tailored to the needs of research institutes, medical institutions, and pharmaceutical companies engaged in cell and gene therapy research. The company’s CRO services encompass gene therapy vector development, gene function research, drug target and efficacy research, and other technical services that support the basic research and early-stage development of cell and gene therapy products.

Cell and Gene Therapy CDMO Services: The company’s CDMO services are designed to support the process development, scale-up, and GMP-compliant production of cell and gene therapy products. The company provides process development and testing, IND-CMC pharmaceutical research, clinical sample production, and commercial product manufacturing services. The company’s CDMO platform is equipped with advanced facilities and technologies for the large-scale production of gene therapy vectors, cell preparations, recombinant proteins, exosomes, and other cell-derived products.

Regenerative Medicine and Anti-Aging Services: The company extends its technical capabilities to the field of regenerative medicine and anti-aging, offering cell preparation, recombinant protein/exosome production, and cell storage services. The company’s services in this segment are aimed at supporting the development and commercialization of innovative therapies for tissue repair, organ regeneration, and age-related diseases.

Technical Support and Consulting Services: The company provides comprehensive technical support and consulting services to clients throughout the entire lifecycle of cell and gene therapy products. The company’s services include project design, technical consultation, regulatory compliance support, and quality management consulting.

Business Strategy

The company’s business strategy is centered on becoming a leading provider of cell and gene therapy technical services, with a focus on technological innovation, quality management, and sustainable development.

The company’s strategy emphasizes the importance of technological innovation as the driving force for growth and competitiveness. The company invests heavily in research and development, establishes technology innovation platforms, and collaborates with leading universities and research institutions to promote the integration of industry, academia, and research. The company continuously optimizes its production processes and quality control technologies to ensure that its technical capabilities remain at the forefront of the industry.

The company’s strategy also prioritizes the development of a comprehensive service platform that covers the entire value chain of cell and gene therapy, from basic research to clinical and commercial production. The company intends to provide one-stop solutions to clients, leveraging its expertise in vector development, process optimization, GMP production, and regulatory compliance. The company’s integrated service model enables it to meet the diverse needs of clients and to support the rapid advancement of cell and gene therapy products.

The company is committed to sustainable development and environmental protection, integrating green and low-carbon concepts into its operations and production processes.

Products and Services

The company provides a comprehensive range of products and services in the field of cell and gene therapy, including:

Gene Therapy Vector Development: The company specializes in the design, construction, and optimization of gene therapy vectors, including viral and non-viral vectors, to support gene function research and drug discovery.

Gene Function Research: The company offers technical services for gene function analysis, target identification, and efficacy evaluation, supporting the basic research and early-stage development of cell and gene therapy products.

Process Development and Testing: The company provides process development, optimization, and testing services for the production of cell and gene therapy products, ensuring scalability, reproducibility, and compliance with regulatory requirements.

IND-CMC Pharmaceutical Research: The company supports clients in the preparation of Investigational New Drug (IND) applications and Chemistry, Manufacturing, and Controls (CMC) documentation, facilitating the transition from research to clinical development.

GMP Production of Clinical Samples and Commercial Products: The company operates GMP-compliant production facilities for the manufacture of clinical trial samples and commercial products, including gene therapy vectors, cell preparations, recombinant proteins, and exosomes.

Cell Preparation and Storage: The company provides cell preparation, expansion, and storage services for regenerative medicine and anti-aging applications, supporting the development and commercialization of innovative therapies.

Recombinant Protein/Exosome Production: The company offers production services for recombinant proteins and exosomes, which are used as therapeutic agents or research tools in cell and gene therapy.

Technical Support and Consulting: The company provides technical support, project design, regulatory compliance consulting, and quality management services to clients throughout the lifecycle of cell and gene therapy products.

Data Security and Information Protection: The company provides data management and information security services to safeguard client and company data, ensuring compliance with relevant laws and regulations.

Geographical Markets Served

The company is headquartered in Shanghai, China, and operates both domestically and internationally.

Customers

The company’s customers include research institutes, medical institutions, and pharmaceutical enterprises engaged in cell and gene therapy research and development. The company provides technical services to a wide range of clients, supporting the basic research, drug discovery, process development, clinical trials, and commercial production of cell and gene therapy products.

Sales and Marketing

The company’s business model is based on providing technical services to research institutes, medical institutions, and pharmaceutical enterprises, suggesting a business-to-business (B2B) marketing approach. The company’s services are promoted through direct engagement with clients, technical support, and consulting services.

Government Regulations

The company strictly abides by the Company Law, Securities Law, and other relevant laws and regulations, and ensures the timely, accurate, and complete disclosure of information. The company’s data security and information protection practices are in compliance with the Cybersecurity Law, Data Security Law, and Personal Information Protection Law of the People’s Republic of China.

History

Obio Technology (Shanghai) Corp., Ltd. was founded in 2013.

Shanghai Obio Technology (Group) Corp. Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** - Biotechnology: 60% - Pharmaceuticals: 25% - Diagnostics: 15% **TOP 3 markets and their percentage shares:** - China: 50% - USA: 30% - Europe: 20% Obio Technology (Shanghai) Corp., Ltd. generates the majority of its revenue from the biotechnology sector, follo...

At which locations are the company’s products manufactured?

**Production Location:** Shanghai, China Obio Technology (Shanghai) Corp., Ltd. mainly produces its products in Shanghai, China. The company is engaged in biotechnological research and development and utilizes its production facilities in Shanghai to manufacture its biopharmaceutical products. Shan...

What strategy does Shanghai Obio Technology (Group) Corp. pursue for future growth?

**Focus on R&D Investments:** 20% of revenue (2025) **Expansion of International Presence:** Planned market entries in Europe and North America (2026) **Strategic Partnerships:** Collaborations with leading biotech companies (2025) Obio Technology (Shanghai) Corp., Ltd. places a strong emph...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific information about the imported raw materials or materials of Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) and their countries of origin for the year 2026. However, it is common for biotechnology companies to import materials such as chemical reagen...

How strong is the company’s competitive advantage?

**Market Share:** Estimated at 10% in the field of gene and cell therapy (2026) **R&D Investments:** 20% of revenue (2025) Obio Technology (Shanghai) Corp., Ltd. has established itself as a significant player in the field of gene and cell therapy. The company's competitive advantage lies...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated for 2026 based on trends from 2023) **Insider Buys/Sells:** No specific data available for 2026, but moderate insider sales have been recorded in recent years. The institutional investor share in Obio Technology (Shanghai) Corp., Ltd. is estimated t...

What percentage market share does Shanghai Obio Technology (Group) Corp. have?

**Market share of Obio Technology (Shanghai) Corp., Ltd.:** Estimated 5-7% (2026) **Top competitors and their market shares:** 1. **WuXi AppTec Co., Ltd.:** 15% 2. **Pharmaron Beijing Co., Ltd.:** 12% 3. **Hangzhou Tigermed Consulting Co., Ltd.:** 10% 4. **Asymchem Laboratories (Tianjin) Co., Ltd.:...

Is Shanghai Obio Technology (Group) Corp. stock currently a good investment?

**Revenue Growth:** 18% (2025) **R&D Expenses:** 25% of revenue (2025) **Market Share in the Biotechnology Sector:** 5% (2025) Obio Technology (Shanghai) Corp., Ltd. shows a strong revenue growth of 18% in 2025, indicating successful expansion and innovation in the biotechnology sector. The com...

Does Shanghai Obio Technology (Group) Corp. pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (as of 2026) Obio Technology (Shanghai) Corp., Ltd. has not distributed any dividends so far. The company operates in the biotechnology sector, where it is common to reinvest profits in research and development to promote long-term growth and innovation. Since the...

New support ticket

Explore

Shanghai Obio Technology (Group) Corp. Stock Value

Shanghai Obio Technology (Group) Corp. Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Obio Technology (Group) Corp. do?

Shanghai Obio Technology (Group) Corp. Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Shanghai Obio Technology (Group) Corp. Stock Value

Shanghai Obio Technology (Group) Corp. Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Obio Technology (Group) Corp. do?

Shanghai Obio Technology (Group) Corp. Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.